Novo Nordisk A/S NVO
40.56 USD -0.83 (-1.99%)
Nov 10, 2026, 3:06 PM EST
40.38 Day range 40.81
35.29 52-week range 63.98
- YTD
- -20.29%
- 1 year
- -11.72%
News
benzinga.com FDA Flags Potential Vision Loss Risk With GLP-1 Drugs, Requiring Weight-Loss Medicines Like Wegovy and Zepbound to Carry New Warning FDA requires new NAION eye warning on all GLP-1 drugs, citing potential increased risk.
benzinga.com Eli Lilly Gains After Jefferies Raises Price Target to Wall Street-High $1,700 Eli Lilly is rising Monday after Jefferies raised its price target to $1,700, the highest target on Wall Street, according to Investing.com.
seekingalpha.com Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth Novo Nordisk is rated BUY with a 6-12 month target price of $57.24, implying ~34% upside from $42.62. Q3 results disprove oral cannibalization fears; a 53% pill surge drove net patient additions,…
fool.com Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway? Novo's third-quarter update was strong, largely due to its oral weight-loss pill. The company has several catalysts ahead that could help power strong results over the medium term.
seekingalpha.com Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers,…
benzinga.com 3 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
zacks.com NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.
defenseworld.net Stock Traders Purchase High Volume of Novo Nordisk A/S Call Options (NYSE:NVO) Novo Nordisk A/S (NYSE: NVO - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders purchased 63,116 call options on the stock. This represents an increase of 14%…
fool.com Novo Nordisk: 3 Key Takeaways for Long-Term Investors Novo Nordisk added 1.3 million patients in the third quarter. Wegovy pill will reach over 20 markets by mid-2027.
fool.com Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next…
seekingalpha.com Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript
247wallst.com Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices…
zacks.com NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's mixed close.
benzinga.com Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines Novo Nordisk (NVO) stock jumped after Q3 earnings beat estimates, driven by record Wegovy pill demand and a raised 2026 outlook.
seekingalpha.com Novo Nordisk Q3: Just The Report I Was Waiting For Novo Nordisk A/S delivered a strong Q3 with a double beat and raised guidance, signaling a turnaround and renewed growth trajectory. Obesity care, especially the Wegovy pill, is driving revenue…
reuters.com GLP-1 drugs help control prediabetes better than current standard medicine Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
barrons.com 2 Reasons for Hope From Novo Nordisk Earnings The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
marketwatch.com Beleaguered Novo offers relief to investors, thanks to Wegovy pill Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
wsj.com Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
reuters.com Novo Nordisk's CFO Karsten Munk Knudsen to leave company Novo Nordisk's CFO Karsten Munk Knudsen to leave company
benzinga.com Novo Nordisk Q3 Adj. EPS $0.87 Beats $0.81 Estimate, Sales $11.900B Beat $11.390B Estimate Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.81 by 7.41 percent. This is a 15.53 percent decrease over earnings of $1.03 per…
cnbc.com Novo raises full-year outlook as Wegovy sales impress Novo raises full-year outlook as Wegovy sales impress
reuters.com Novo Nordisk Q3 profit beats forecast; raises 2026 guidance Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds plunge to 22% as Wall Street digests midterm results, a tech futures drop, and key earnings.
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
fool.com 3 Dirt Cheap Dividend Stocks to Buy in November 2026 AT&T, Novo Nordisk, and Vici Properties have struggled this year but remain high-quality investments. Their valuations are incredibly low, giving investors the potential to benefit from high…
benzinga.com Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
benzinga.com Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
benzinga.com Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED) Novo Nordisk fails to block Eli Lilly’s weight-loss drug ads as a judge finds little evidence of market impact or lasting harm.
benzinga.com Novo Nordisk To Present 12 New Semaglutide And MASH Research Abstracts At AASLD’s The Liver Meeting 2026 The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASHNew post hoc data…
benzinga.com More Americans Now Take GLP-1 Drugs for Weight Loss Than Diabetes as Food, Alcohol and Apparel Habits Shift, Survey Finds GLP-1 users cut sweets and switch clothing sizes as weight management becomes top use.
benzinga.com Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
benzinga.com QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
benzinga.com BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40 BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.
benzinga.com Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’ PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.
benzinga.com FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outlook remains unchanged with 2027 launch goal.
benzinga.com Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms Anthropic launches a $100 million academy to train 10,000 AI engineers by 2027 as demand for AI talent surges.- benzinga.com Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory Action On The BLA https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html
benzinga.com Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
benzinga.com Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.- benzinga.com Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooledsemaglutide 7.2 and 2.4 mg) reduced liver fat in adults…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients switching to oral semaglutide also lost weight.
benzinga.com Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED) Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
benzinga.com Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo Nordisk's semaglutide treatments.- benzinga.com Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To Tirzepatide Up To 15 mg Novo’s Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro®…
benzinga.com Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as…
benzinga.com Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question — Scientist Says He Had Already Studied the Enzymes for 4 Years Anthropic’s Claude enzyme discovery claim faces scrutiny after a biologist questioned whether prior research influenced the AI’s findings.
benzinga.com Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s…